Company: ARVN
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001655759-25-000075
Chunk: 60

Company: ARVINAS, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 60
---
.

(3) Reflects matching contributions paid under the terms of our 401(k) plan.

(4) Mr. Saik was appointed as our Chief Financial Officer, Treasurer and principal financial officer effective June 24, 2024.

(5) Dr. Teel served as our interim Chief Financial Officer, Treasurer and principal financial officer, from February 29, 2024 to June 24, 2024.

(6) Mr. Cassidy served as our Chief Financial Officer, Treasurer and principal financial officer until February 29, 2024.

<div align='center'>43</div>

(7) Dr. Berkowitz was appointed as our Chief Medical Officer effective March 18, 2024.

(8) Dr. Cacace was appointed as our Chief Scientific Officer effective June 17, 2024.

(9) Dr. Taylor served as our Chief Scientific Officer until June 17, 2024, at which time he was appointed President of R&D.

#### Grants of Plan-Based Awards
The following table sets forth information regarding non-equity and equity awards granted to each of our named executive officers during the year ended December 31, 2024. All non-equity incentive plan awards were made pursuant to our annual cash incentive plan described in more detail above. We granted Options and RSUs to each of Noah Berkowitz, M.D., Ph.D., and Andrew Saik as an inducement material to entering into employment with us and these Options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to the 2018 Plan. We granted Options and RSUs to Angela Cacace, Ph,D., John Houston, Ph.D., Randy Teel, Ph.D., and Ian Taylor, Ph.D., in 2024 in recognition of performance in 2023 . We also granted additional Options and RSUs to Dr. Cacace and Dr. Teel in 2024 in connection with being named as Chief Scientific Officer and Chief Business Officer, respectively . All Options granted in 2024 consisted of options to purchase shares of our common stock with an exercise price equal to the fair market value of our common stock on the date of grant. All such equity awards were granted under our 2018 Plan, other than our inducement awards granted to Dr. Berkowitz and Mr. Saik and unless otherwise disclosed below. Mr. Cassidy was not granted any equity awards during 2024. The vesting schedule of each